Medicines New Zealand Unveils 2022 Transfer of Value Reports to Enhance Transparency

Medicines New Zealand is delighted to announce the launch of the 2022 Transfer of Value reports. These reports, representing the organisation’s second annual publication, offer a transparent snapshot of the financial interactions between biopharmaceutical companies and healthcare professionals. This initiative underscores our unwavering commitment to transparency and ethical standards within the industry.

Dr Graeme Jarvis, CEO of Medicines New Zealand, remarked on the release, “This information is what the joint project between industry and healthcare practitioners was designed to deliver.”

The reports aim to shed light on the financial relationships and interactions between biopharmaceutical companies and healthcare professionals. They seek to bolster transparency and uphold ethical standards within the industry.

“Public reporting of payments made by the biopharmaceutical industry to healthcare professionals is the right thing to do from a transparency perspective,” said Dr Jarvis. “This commitment allows patients and the public to gain insight into the nature of these interactions and have confidence in the ethical standards and patient-centric approach of healthcare professionals in New Zealand.”

The 2022 Transfer of Value reports provide a comprehensive overview of the financial interactions between Medicines New Zealand member companies and healthcare professionals. These interactions include sponsorships for healthcare providers to attend medical education events and conferences, which ultimately benefit patient care and contribute to the continuous improvement of healthcare practices.

Medicines New Zealand invites all interested parties to access the Transfer of Value reports from its member companies. The reports serve as a valuable resource for those seeking a deeper understanding of the financial relationships that drive advancements in patient care.